New inhaled powder for COPD heads into first human tests

NCT ID NCT07567872

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests an inhaled powder called HRS-9821 in healthy volunteers and people with COPD. The main goal is to check safety and how the body handles the drug. About 48 participants will receive either the drug or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HRS-9821 powder for inhalation

What this could lead to

If successful, this could lead to a new inhaled treatment option for COPD that helps control the disease.

What could go wrong

This is a very early Phase 1 trial with only 48 participants, focused on safety. It is too small and early to know if the drug will work or be safe long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, 610044, China

    Contact

    Contact